ReviewBiology2022
Atrial Fibrillation in β-Thalassemia: Overview of Mechanism, Significance and Clinical Management.
Review in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Exercise reveals precocious-subclinical cardiovascular and muscular dysfunction in transfusion dependent beta-thalassemia (TDT) patients without cardiac iron overload.Journal of translational medicine · 2026Article
- Atrial Fibrillation in Infiltrative Cardiomyopathies: From Atrial Cardiomyopathy Imaging to Targeted Management-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study.Blood advances · 2026Article
- Assessing Cardiac Mechanical Dysfunction in Transfusion-Dependent β-Thalassemia With History of Atrial Fibrillation: The Role of Speckle Tracking Echocardiography.Echocardiography (Mount Kisco, N.Y.) · 2026Observational
- Association between epicardial adipose tissue and transfusion-dependent β-thalassemia.The international journal of cardiovascular imaging · 2025Observational
- Cardiac Conduction Disorders Due to Acquired or Genetic Causes in Young Adults: A Review of the Current Literature.Journal of the American Heart Association · 2025Review
- Cardiac Magnetic Resonance in the Assessment of Atrial Cardiomyopathy and Pulmonary Vein Isolation Planning for Atrial Fibrillation.Journal of imaging · 2025Review
- Cardiac injury caused by iron overload in thalassemia.Frontiers in pediatrics · 2025Review
- Identification and Functional Investigation ofDiagnostics (Basel, Switzerland) · 2024Article
- Antioxidative effects of N-acetylcysteine in patients with β-thalassemia: A quick review on clinical trials.Health science reports · 2024Article
- Association between Epicardial Adipose Tissue and Atrial Fibrillation in Patients with Transfusion-Dependent β-Thalassemia.Journal of clinical medicine · 2024Article
- Cardiac complications in thalassemia throughout the lifespan: Victories and challenges.Annals of the New York Academy of Sciences · 2023Review
- Association Between β-thalassemia and Atrial Fibrillation: Insights from the United States National Inpatient Sample.The Journal of innovations in cardiac rhythm management · 2023Article
- Discovery ofBiology · 2023Article
- Special Issue: "Biophysics, Arrhythmias and Pacing".Biology · 2023Article
- Article
- Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study.Scientific reports · 2022Article
- Metabolic Inflexibility as a Pathogenic Basis for Atrial Fibrillation.International journal of molecular sciences · 2022Review
- T1 mapping and speckle tracking echocardiography for the assessment of early mechanical dysfunction in transfusion-dependent β-thalassemia with normal T2.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic ResonanceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalassemia is an inherited blood disorder with worldwide distribution. Transfusion and chelation therapy have radically improved the prognosis of β-thalassemic patients in the developed world, but this has led to the development of new chronic cardiac complications like atrial fibrillation (AF). Prevalence of AF in patients with β-thalassemia is higher than in the general population, ranging from 2 to 33%. Studies are lacking, and the little evidence available comes from a small number of observational studies. The pathophysiology is not well understood but, while iron overload seems to be the principal mechanism, AF could develop even in the absence of iron deposition. Furthermore, the clinical presentation is mainly paroxysmal, and patients are highly symptomatic. The underlying disease, the pathophysiology, and the clinical presentation require a different management of AF in β-thalassemia than in the general population. Rhythm control should be preferred over rate control, and the most important antiarrhythmic therapy is represented by chelation drugs. Thromboembolic risk is high, but the available risk scores are not validated in β-thalassemia, and the choice of anticoagulation therapy should be considered early. The main purpose of this review is to summarize the actual knowledge about AF in β-thalassemia, with a specific focus on the clinical management of these complex patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.